Direct‑acting antiviral treatment is safe and effective for chronic HCV patients with psychiatric disorders

Okano,Hiroshi; Takenaka,Takanori; Asakawa,Hiroki; Tsuruga,Satomi; Kumazawa,Hiroaki; Isono,Yoshiaki; Tanaka,Hiroki; Matsusaki,Shimpei; Sase,Tomohiro; Saito,Tomonori; Mukai,Katsumi; Nishimura,Akira

doi:10.3892/etm.2023.12100

Direct‑acting antiviral treatment is safe and effective for chronic HCV patients with psychiatric disorders

Authors:
- Hiroshi Okano
- Takanori Takenaka
- Hiroki Asakawa
- Satomi Tsuruga
- Hiroaki Kumazawa
- Yoshiaki Isono
- Hiroki Tanaka
- Shimpei Matsusaki
- Tomohiro Sase
- Tomonori Saito
- Katsumi Mukai
- Akira Nishimura
View Affiliations

Affiliations: Department of Gastroenterology, Suzuka General Hospital, Suzuka, Mie 513‑8630, Japan
Published online on: July 7, 2023 https://doi.org/10.3892/etm.2023.12100
Article Number: 402

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although most patients with hepatitis C virus (HCV) infection have been cured since the introduction of direct‑acting antiviral (DAA) treatments, whether patients with psychiatric disorders and chronic HCV infection receive benefits from DAA treatments remain unclear. The efficacy and safety of DAA treatment were compared between patients with and without psychiatric disorders. Data were retrospectively collected from medical records at the Suzuka General Hospital (Japan) between September 2014 and December 2021. The study was an observational, single‑center study. Fisher's exact test, Mann‑Whitney U test and Friedman's test were used for the comparisons between groups. Patients with HCV infection who had been started on DAA treatments were included. In total, 15 HCV cases with psychiatric disorders (P) and 209 HCV cases with nonpsychiatric disorders (NP) were started on DAA treatments for HCV infection. Patients in group P were younger (55±13.9 years) compared with those in group NP (68±13.0 years). A total of 12 patients (80%) in group P achieved and 188 patients (90%) in group NP achieved sustained virologic response (SVR), with no significant difference between the two groups. The remaining three patients in group P who did not achieve SVR included two drop‑out cases. Regarding the laboratory data at the end of DAA treatments and SVR, there were no significant differences between the two groups. There were no cases of discontinuation or reduction of medication due to psychiatric disorders during DAA treatment. DAA treatment for HCV infection is effective, tolerable and safe for psychiatric patients, as well as patients without psychiatric disorders. Psychiatric patients with HCV infection should undergo DAA treatment to prevent progression to liver failure and/or cancer.

View Figures

View References

1	Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014.PubMed/NCBI View Article : Google Scholar
2	Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, et al: Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat. 21:762–768. 2014.PubMed/NCBI View Article : Google Scholar
3	Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA and Kumada H: Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 61:1523–1532. 2015.PubMed/NCBI View Article : Google Scholar
4	Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis. 15:645–653. 2015.PubMed/NCBI View Article : Google Scholar
5	Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, et al: Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: A nationwide retrospective study in Japan. J Gastroenterol. 53:119–128. 2018.PubMed/NCBI View Article : Google Scholar
6	Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, et al: Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 89:91–98. 2017.PubMed/NCBI View Article : Google Scholar
7	Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB and Sulkowski MS: Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann Intern Med. 166:637–648. 2017.PubMed/NCBI View Article : Google Scholar
8	Backus LI, Belperio PS, Shahoumian TA and Mole LA: . Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology. 69:487–497. 2019.PubMed/NCBI View Article : Google Scholar
9	Hauser P and Kern S: Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol. 7:1921–1935. 2015.PubMed/NCBI View Article : Google Scholar
10	Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S, Hellstrand K, et al: Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 52:430–435. 2010.PubMed/NCBI View Article : Google Scholar
11	Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H and Construct Group: Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 8:45–49. 2002.PubMed/NCBI View Article : Google Scholar
12	Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K and Kumada H: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry Clin Neurosci. 54:565–572. 2000.PubMed/NCBI View Article : Google Scholar
13	Zignego AL and Craxì A: Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 12:611–636. 2008.PubMed/NCBI View Article : Google Scholar
14	Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D and Pariante CM: Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 57:1379–1390. 2012.PubMed/NCBI View Article : Google Scholar
15	Cheng JS, Hu JH, Chang MY, Lin MS, Ku HP, Chien RN and Chang ML: Hepatitis C-associated late-onset schizophrenia: A nationwide, population-based cohort study. J Psychiatry Neurosci. 46:E583–E591. 2021.PubMed/NCBI View Article : Google Scholar
16	Back D, Belperio P, Bondin M, Negro F, Talal AH, Park C, Zhang Z, Pinsky B, Crown E, Mensa FJ and Marra F: Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. J Viral Hepat. 26:951–960. 2019.PubMed/NCBI View Article : Google Scholar
17	de Gennaro N, Diella L, Monno L, Angarano G, Milella M and Saracino A: Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders. BMC Infect Dis. 20(196)2020.PubMed/NCBI View Article : Google Scholar
18	Sackey B, Shults JG, Moore TA, Rogers R, Mehvar M and King JG: Evaluating psychiatric outcomes associated with direct-acting antiviral treatment in veterans with hepatitis C infection. Ment Health Clin. 8:116–121. 2018.PubMed/NCBI View Article : Google Scholar
19	Okano H, Murakami M, Asakawa H, Tsuruga S, Tochio T, Kumazawa H, Sakuno T, Isono Y, Tanaka H, Matsusaki S, et al: Acute hepatitis C virus infections in spouses: The utility of a genetic analysis of the hepatitis C virus hypervariable region sequence for identifying the infectious source. Arch Clin Med Case Rep. 5:537–548. 2021.
20	Yamadate S and Nakayama T: The future topics of discussion on JSCC recommended methods. Rinsho Byori. 64:544–549. 2016.PubMed/NCBI(In Japanese).
21	Tahata Y, Sakamori R and Takehara T: Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. Glob Health Med. 3:321–334. 2021.PubMed/NCBI View Article : Google Scholar
22	Phan SV: Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 51:211–219. 2016.PubMed/NCBI View Article : Google Scholar
23	Gaudiano BA, Weinstock LM and Miller IW: Improving treatment adherence in bipolar disorder: A review of current psychosocial treatment efficacy and recommendations for future treatment development. Behav Modif. 32:267–301. 2008.PubMed/NCBI View Article : Google Scholar
24	Lazary J, Pogany L, De Las Cuevas C, Villasante-Tezanos GA and De Leon J: Adherence to psychiatric medications: Comparing patients with schizophrenia, bipolar disorder and major depression. Neuropsychopharmacol Hung. 23:363–373. 2021.PubMed/NCBI
25	Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, et al: A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol. 19(85)2019.PubMed/NCBI View Article : Google Scholar
26	Braude MR, Phan T, Dev A and Sievert W: Determinants of hepatitis C virus prevalence in people with serious mental illness: A systematic review and meta-analysis. J Clin Psychiatry. 83(21r14079)2021.PubMed/NCBI View Article : Google Scholar
27	Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, et al: Liver diseases in the Asia-Pacific region: A lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 5:167–228. 2020.PubMed/NCBI View Article : Google Scholar